End-of-day quote
Dhaka S.E.
06:00:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
118.9
BDT
|
+0.68%
|
|
-2.46%
|
-18.67%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
33,864
|
28,065
|
79,096
|
68,969
|
65,222
|
53,043
|
-
|
-
|
Enterprise Value (EV)
1 |
33,864
|
37,934
|
86,052
|
80,148
|
65,222
|
58,999
|
53,921
|
48,583
|
P/E ratio
|
11.2
x
|
7.98
x
|
15.4
x
|
13.5
x
|
14.1
x
|
9.67
x
|
7.88
x
|
6.42
x
|
Yield
|
1.8%
|
2.17%
|
1.97%
|
2.26%
|
-
|
3.49%
|
4.42%
|
5.37%
|
Capitalization / Revenue
|
1.48
x
|
1.1
x
|
2.68
x
|
1.99
x
|
1.66
x
|
1.19
x
|
1.05
x
|
0.93
x
|
EV / Revenue
|
1.48
x
|
1.48
x
|
2.92
x
|
2.31
x
|
1.66
x
|
1.33
x
|
1.07
x
|
0.85
x
|
EV / EBITDA
|
5.64
x
|
5.64
x
|
11.1
x
|
9.38
x
|
-
|
5.92
x
|
4.75
x
|
3.73
x
|
EV / FCF
|
-23.2
x
|
11.5
x
|
24.6
x
|
34.9
x
|
-
|
12.1
x
|
9.43
x
|
7.07
x
|
FCF Yield
|
-4.3%
|
8.7%
|
4.06%
|
2.87%
|
-
|
8.3%
|
10.6%
|
14.1%
|
Price to Book
|
1.14
x
|
0.86
x
|
2.14
x
|
1.7
x
|
-
|
1.07
x
|
0.98
x
|
0.88
x
|
Nbr of stocks (in thousands)
|
446,112
|
446,112
|
446,112
|
446,112
|
446,112
|
446,112
|
-
|
-
|
Reference price
2 |
75.91
|
62.91
|
177.3
|
154.6
|
146.2
|
118.9
|
118.9
|
118.9
|
Announcement Date
|
11/11/19
|
11/11/20
|
11/2/21
|
11/8/22
|
11/1/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22,817
|
25,612
|
29,494
|
34,669
|
39,267
|
44,506
|
50,423
|
57,171
|
EBITDA
1 |
6,009
|
6,723
|
7,765
|
8,543
|
-
|
9,974
|
11,358
|
13,037
|
EBIT
1 |
5,066
|
5,609
|
6,651
|
6,901
|
7,216
|
7,955
|
9,111
|
10,469
|
Operating Margin
|
22.2%
|
21.9%
|
22.55%
|
19.91%
|
18.38%
|
17.87%
|
18.07%
|
18.31%
|
Earnings before Tax (EBT)
1 |
3,946
|
4,653
|
6,378
|
6,687
|
6,069
|
7,122
|
8,499
|
10,153
|
Net income
1 |
3,033
|
3,515
|
5,141
|
5,123
|
4,612
|
5,251
|
6,244
|
7,464
|
Net margin
|
13.29%
|
13.72%
|
17.43%
|
14.78%
|
11.74%
|
11.8%
|
12.38%
|
13.06%
|
EPS
2 |
6.800
|
7.882
|
11.49
|
11.48
|
10.34
|
12.30
|
15.10
|
18.53
|
Free Cash Flow
1 |
-1,457
|
3,299
|
3,498
|
2,299
|
-
|
4,894
|
5,719
|
6,868
|
FCF margin
|
-6.38%
|
12.88%
|
11.86%
|
6.63%
|
-
|
11%
|
11.34%
|
12.01%
|
FCF Conversion (EBITDA)
|
-
|
49.07%
|
45.04%
|
26.91%
|
-
|
49.07%
|
50.35%
|
52.68%
|
FCF Conversion (Net income)
|
-
|
93.86%
|
68.04%
|
44.87%
|
-
|
93.21%
|
91.59%
|
92.02%
|
Dividend per Share
2 |
1.364
|
1.364
|
3.500
|
3.500
|
-
|
4.155
|
5.255
|
6.385
|
Announcement Date
|
11/11/19
|
11/11/20
|
11/2/21
|
11/8/22
|
11/1/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
9,869
|
6,956
|
11,179
|
-
|
5,956
|
878
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
4,460
|
Leverage (Debt/EBITDA)
|
-
|
1.468
x
|
0.8958
x
|
1.309
x
|
-
|
0.5972
x
|
0.0773
x
|
-
|
Free Cash Flow
1 |
-1,457
|
3,299
|
3,498
|
2,299
|
-
|
4,894
|
5,719
|
6,868
|
ROE (net income / shareholders' equity)
|
10.6%
|
11.2%
|
14.8%
|
13.2%
|
-
|
11.4%
|
12.7%
|
14.1%
|
ROA (Net income/ Total Assets)
|
6.53%
|
7.08%
|
10%
|
-
|
-
|
7.7%
|
9.1%
|
10.7%
|
Assets
1 |
46,476
|
49,642
|
51,182
|
-
|
-
|
68,190
|
68,615
|
69,760
|
Book Value Per Share
2 |
66.30
|
72.80
|
83.00
|
91.00
|
-
|
111.0
|
122.0
|
135.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2,244
|
2,526
|
2,915
|
-
|
2,090
|
1,000
|
1,000
|
Capex / Sales
|
-
|
8.76%
|
8.56%
|
8.41%
|
-
|
4.7%
|
1.98%
|
1.75%
|
Announcement Date
|
11/11/19
|
11/11/20
|
11/2/21
|
11/8/22
|
11/1/23
|
-
|
-
|
-
|
Last Close Price
118.9
BDT Average target price
168.3
BDT Spread / Average Target +41.58% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.67% | 452M | | +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B |
Other Pharmaceuticals
|